Otonomy Receives $38,500,000 Series B Financing Round
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=65ce5abd-c4da-4544-b364-ca39cd5eef63&Preview=1 - Date
8/30/2010 - Company Name
Otonomy - Mailing Address
5626 Oberlin Dr. San Diego, CA 92121 - Company Description
Otonomy is a clinical stage biopharmaceutical company developing novel drug therapies for disorders of the inner and middle ear. This field represents a large opportunity as there are no approved drug treatments for the nearly 30 million Americans facing debilitating hearing and balance disorders such as Ménière’s disease, sudden sensorineural hearing loss, noise-induced hearing loss, age-related hearing impairment, and tinnitus. - Website
http://www.otonomy.com - Transaction Type
Venture Equity - Transaction Amount
$38,500,000 - Transaction Round
Series B - Proceeds Purposes
oceeds from the financing will support Otonomy’s first two programs through pivotal clinical studies as well as expansion of the Company’s pipeline of locally delivered drugs to treat disorders of the ear. - M&A Terms
- Venture Investor
Novo A/S - Venture Investor
Rivervest Venture Partners - Venture Investor
Domain Associates - Venture Investor
TPG Biotechnology Partners - Venture Investor
Avalon Ventures
